XML 58 R36.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes (Tables)
 12 Months Ended
Dec. 31, 2024
Income Tax Disclosure [Abstract]  
Schedule of Effective Income Tax Rate Reconciliation
A reconciliation between income tax benefit and the expected tax benefit at the statutory rate for the years ended December 31, 2024 and 2023 are as follows:
 For the Year Ended
December 31,
 20242023
Statutory federal income tax rate21.0 %21.0 %
State income taxes, net of federal benefit5.9 %6.1 %
Research and development tax credits4.3 %3.7 %
Orphan drug tax credits4.4 %4.9 %
Expiration of NOLs/credits(6.1)%(6.3)%
Other(0.3)%1.5 %
Stock based compensation(1.7)%(2.5)%
Change in valuation allowance(27.5)%(28.4)%
Effective income tax rate— %— %
Schedule of Components of Deferred Tax Assets
The principal components of the Company’s deferred tax assets at December 31, 2024 and December 31, 2023, respectively, are as follows:
December 31,
20242023
Deferred Tax Assets:
NOL carryforwards$104,122 $91,036 
Research and development tax credit carryforwards 18,220 16,973 
Orphan drug tax credit carryforwards26,885 24,983 
Depreciation and amortization4,597 5,552 
Capitalized research and development expenditures41,283 42,271 
Stock options5,571 4,857 
Accrued expenses and other154 973 
Oberland agreement9,336 11,640 
Lease liability807 763 
Total gross deferred tax asset210,975 199,048 
Valuation allowance(210,112)(198,212)
Net deferred tax asset$863 $836 
Deferred tax liabilities:
Right of use asset(863)(836)
Total gross deferred tax liabilities$(863)$(836)
Net deferred tax assets (liabilities)$— $—